Search Results
1 - Medtronic Continues Membership in the Dow Jones Sustainability Index and FTSE4Good Index
MINNEAPOLIS-(Business Wire)-September 28, 2009 - Recognizing its leadership in meeting the needs of economic, environmental, and social stakeholders, Medtronic, Inc. (NYSE: MDT) has been named a member company in the Dow Jones Sustainability Index (DJSI) for North America and the FTSE4Good Index...
2 - New Clinical Data on Medtronic Transcatheter Heart Valves Featured in More Than 25 Presentations at TCT 2009
MINNEAPOLIS-(Business Wire)-September 22, 2009 - With the promise of percutaneous treatments for patients with diseased heart valves growing, Medtronic, Inc. (NYSE: MDT), announced today that more presentations than ever before – at least 25 – on the company’s portfolio of unique transcatheter...
3 - Physio-Control Receives Market Approval from Health Canada for LIFEPAK® 15 Monitor/Defibrillator
REDMOND, Wash.-(Business Wire)-September 22, 2009 - Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc., (NYSE: MDT) announced today it received approval by Health Canada to market the LIFEPAK 15 monitor/defibrillator within Canada. Official license notification was received on...
4 - Medtronic’s Resolute® Drug-Eluting Stent Maintains Strong, Sustained Efficacy and Safety in Long-Term Follow-up
SAN FRANCISCO-(Business Wire)-September 21, 2009 - New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term patient follow-up...
5 - ENDEAVOR® Stent Reduced Risk of Heart Attack/Cardiac Death by 48% at Three Years Compared to Taxus® Stent in Large Study
SAN FRANCISCO-(Business Wire)-September 21, 2009 - Anticipating a change in the practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT), announced today that the latest findings from the ENDEAVOR IV clinical trial – a large study comparing two drug-eluting coronary stents head-to-head...
6 - Medtronic, Inc. Launches Innovative Cement Delivery System for KYPHON® Balloon Kyphoplasty
MINNEAPOLIS-(Business Wire)-September 21, 2009 - Medtronic, Inc. (NYSE:MDT), today announced the full U.S. launch of the KYPHON Cement Delivery System (CDS), adding an innovative bone cement delivery option to its extensive KYPHON Balloon Kyphoplasty product portfolio for the treatment of...
7 - Medtronic Expects New Data on Drug-Eluting Stents and Transcatheter Heart Valves to Feature at TCT 2009
MINNEAPOLIS-(Business Wire)-September 18, 2009 - Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its...
8 - Medtronic and W.L. Gore & Associates Settle Patent Dispute
MINNEAPOLIS-(Business Wire)-September 16, 2009 - Medtronic, Inc. (NYSE: MDT) today announced that it has settled a patent lawsuit it initiated against W.L. Gore & Associates. Medtronic sued W.L. Gore in 2006 for patent infringement of selected patents in Medtronic’s Jervis and Wiktor patent...
9 - Medtronic Launches New and Innovative Intraoperative Nerve Integrity Monitors for Surgeons
MINNEAPOLIS-(Business Wire)-September 16, 2009 - Medtronic (NYSE: MDT) recently announced the launch of the NIM-Response® 3.0 and NIM-Neuro® 3.0 intraoperative nerve integrity monitors designed for a variety of surgeons, including ear, nose, and throat (ENT); endocrine; general; and peripheral...
10 - Early Research Shows Cardiac Resynchronization Therapy May Benefit Patients with Ejection Fractions above 35 Percent
MINNEAPOLIS & BOSTON-(Business Wire)-September 15, 2009 - Early findings from a Medtronic, Inc. (NYSE: MDT) sponsored study show heart failure patients with moderate ejection fractions, over 35 percent, may receive comparable benefits from cardiac resynchronization therapy (CRT) as compared to...
11 - Alnylam and Medtronic Present New Late-Stage Pre-clinical Data on ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington’s Disease
VANCOUVER, B.C.-(Business Wire)-September 15, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from...
12 - IMPROVE HF, a Guideline-Focused Performance Improvement Study, Demonstrates Significantly Improved Outpatient Heart Failure Quality of Care
MINNEAPOLIS & BOSTON-(Business Wire)-September 14, 2009 - A process improvement program significantly improved the quality of care on six of seven guideline-recommended care measures in the largest U.S. outpatient heart failure clinical study. Twenty-four month findings from IMPROVE HF, (The...
13 - Medtronic Study Shows Fluid Monitoring More Accurate Than Weight Measures for Heart Failure Patients
MINNEAPOLIS & BOSTON-(Business Wire)-September 14, 2009 - Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today...
14 - FDA Classifies Voluntary Notification Related to SC Catheters and IsoMed Pump Incompatibility as Class I Recall
MINNEAPOLIS-(Business Wire)-September 14, 2009 - Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has classified its letters to physicians related to the incompatibility of its Sutureless Connector (SC) intrathecal catheters with the IsoMed® constant-flow...
15 - Medtronic Recognizes Recipient of World Journal of Surgery ''Best of 2008'' Award
MINNEAPOLIS-(Business Wire)-September 11, 2009 - Medtronic (NYSE: MDT) today recognized Henning Dralle, M.D., Professor at the University of Halle-Wittenberg in Halle, Germany, who received the World Journal of Surgery award for Best Paper of 2008. Professor Dralle received the award as lead...
16 - Medtronic CFO Gary Ellis to Speak at the Morgan Stanley Global Health Care Conference
MINNEAPOLIS-(Business Wire)-September 3, 2009 - Medtronic, Inc. (NYSE: MDT), today announced it will participate in the 2009 Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009, in New York. Gary Ellis, senior vice president and chief financial officer at Medtronic...
17 - Medtronic Initiates Phase II Hepatitis C Clinical Study ''COPE-HCV'' to Determine Tolerability and Safety of Continuous Interferon Infusion for Patients with HCV
MINNEAPOLIS-(Business Wire)-September 2, 2009 - Medtronic, Inc. (NYSE: MDT), today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever...
18 - New Diabetes Device May Be Next Step in Quest for Artificial Pancreas
MINNEAPOLIS-(Business Wire)-September 2, 2009 - At this year’s annual meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD) in Ljubljana, Slovenia, Medtronic, Inc. (NYSE: MDT) announced the global launch of a novel technology designed to provide additional protection...
19 - Medtronic Announces Organizational and Leadership Changes
MINNEAPOLIS-(Business Wire)-August 31, 2009 - Medtronic, Inc. (NYSE:MDT), announced today a series of organizational and leadership changes that support the company’s One Medtronic initiative. Effective immediately, the company will consolidate its businesses into two operating groups, each...
20 - New REVERSE Analysis Reinforces Improvements Seen in Mild Heart Failure Patients with Cardiac Resynchronization Therapy
MINNEAPOLIS & BARCELONA-(Business Wire)-August 30, 2009 - Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE...
